Breaking News Instant updates and real-time market news.

CLVS

Clovis

$35.77

-1.51 (-4.05%)

, AZN

AstraZeneca

$32.09

-0.17 (-0.53%)

10:43
10/07/16
10/07
10:43
10/07/16
10:43

Clovis data don't necessarily dampen odds of rucaparib approval, TheStreet says

After Clovis Oncology (CLVS) presented more detailed data from two previously announced clinical trials of its PARP inhibitor, rucaparib, TheStreet's Adam Feuerstein said none of the new data "necessarily dampen odds of rucaparib's approval in ovarian cancer," and attributed the slide in the stock to the potential that could be inferior to AstraZeneca's (AZN) Lynparza and to the chance that takeover speculation may "be subsiding." While comparing drugs across trials is challenging and the enrollment eligibility requirements for the two trials were "somewhat different," neither of those facts have stopped investors from making a judgment about rucaparib, concluded Feuerstein. Reference Link

CLVS

Clovis

$35.77

-1.51 (-4.05%)

AZN

AstraZeneca

$32.09

-0.17 (-0.53%)

  • 07

    Oct

  • 06

    Nov

  • 16

    Nov

  • 23

    Feb

CLVS Clovis
$35.77

-1.51 (-4.05%)

09/21/16
JANY
09/21/16
DOWNGRADE
JANY
Neutral
Clovis downgraded to Neutral from Buy at Janney Capital
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
10/04/16
PIPR
10/04/16
NO CHANGE
Target $42
PIPR
Neutral
Clovis price target raised to $42 from $14 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Clovis Oncology (CLVS) to $42 after taking a "comprehensive look" at the PARP inhibitor landscape in ovarian cancer and beyond. The company's PARP inhibitor rucaparib has demonstrated an active profile in ovarian cancer and all signs point to an approval in the 3L+ setting early next year, Breazzano tells investors in a research note. The analyst, however, believes the ultimate key is success in the earlier maintenance setting, and he thinks the race may still be Tesaro's (TSRO) niraparib's to lose. Breazzano keeps a Neutral rating on Clovis.
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.
AZN AstraZeneca
$32.09

-0.17 (-0.53%)

09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

ELY

Callaway Golf

$14.14

0.12 (0.86%)

07:09
09/20/17
09/20
07:09
09/20/17
07:09
Recommendations
Callaway Golf analyst commentary  »

Callaway Golf EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$252.46

-0.62 (-0.24%)

07:09
09/20/17
09/20
07:09
09/20/17
07:09
Recommendations
Boeing analyst commentary  »

Boeing price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

MTCH

Match Group

$23.45

-0.02 (-0.09%)

07:08
09/20/17
09/20
07:08
09/20/17
07:08
Recommendations
Match Group analyst commentary  »

Match Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:08
09/20/17
09/20
07:08
09/20/17
07:08
Hot Stocks
Breaking Hot Stocks news story on General Mills »

General Mills down 4.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

KPTI

Karyopharm

$10.52

-0.34 (-3.13%)

07:07
09/20/17
09/20
07:07
09/20/17
07:07
Hot Stocks
Karyopharm: 'successful' outcome from Phase 2 portion of Phase 2/3 SEAL study »

Karyopharm reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:05
09/20/17
09/20
07:05
09/20/17
07:05
Hot Stocks
General Mills CEO says FY18 priority is 'strengthening our topline performance' »

"Our number one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SNY

Sanofi

$49.10

0.46 (0.95%)

, ALNY

Alnylam

$75.04

-0.96 (-1.26%)

07:05
09/20/17
09/20
07:05
09/20/17
07:05
Hot Stocks
Sanofi and Alnylam report topline results of patisiran in ATTR amyloidosis »

Sanofi's (SNY)…

SNY

Sanofi

$49.10

0.46 (0.95%)

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ADBE

Adobe

$156.60

0.83 (0.53%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Recommendations
Adobe analyst commentary  »

Adobe near-term weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

WDC

Western Digital

$89.92

0.74 (0.83%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Technical Analysis
Technical View: Western Digital falls as Toshiba selects Bain-led group as buyer »

Toshiba (TOSBF, TOSYY)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Hot Stocks
General Mills CEO says 'confident in improved momentum' for rest of year »

CEO Harmening said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SIX

Six Flags

$56.75

-0.32 (-0.56%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
Six Flags says no expected material impact from Mexico earthquake »

Six Flags Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

PG

Procter & Gamble

$94.17

1.02 (1.10%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
Procter & Gamble: Peltz 'lacks specific qualities' P&G seeking in board members »

The Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
General Mills reports Q1 gross margin down 150 bps to 34.8% »

Gross margin decreased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

07:02
09/20/17
09/20
07:02
09/20/17
07:02
General news
MBA Mortgage Applications Composite Index data reported »

Week of 9/15 MBA Mortgage…

IDN

Intellicheck

07:02
09/20/17
09/20
07:02
09/20/17
07:02
Initiation
Intellicheck initiated  »

Intellicheck initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

, SNY

Sanofi

$49.10

0.46 (0.95%)

07:02
09/20/17
09/20
07:02
09/20/17
07:02
Hot Stocks
Alnylam, Sanofi say APOLLO Phase 3 study met primary, secondary endpoints »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

SNY

Sanofi

$49.10

0.46 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:02
09/20/17
09/20
07:02
09/20/17
07:02
Earnings
General Mills backs FY18 adjusted EPS growth of 1%-2%, consensus $3.10 »

Reaffirms fiscal 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:00
09/20/17
09/20
07:00
09/20/17
07:00
Earnings
General Mills reports Q1 adjusted EPS 71c, consensus 76c »

Reports Q1 revenue $3.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

CELG

Celgene

$143.47

0.63 (0.44%)

, XLRN

Acceleron

$38.97

-0.41 (-1.04%)

06:59
09/20/17
09/20
06:59
09/20/17
06:59
Recommendations
Celgene, Acceleron analyst commentary  »

Jefferies sees Celgene…

CELG

Celgene

$143.47

0.63 (0.44%)

XLRN

Acceleron

$38.97

-0.41 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 21

    Sep

ACH

Aluminum Corp. of China

$21.31

0.28 (1.33%)

06:59
09/20/17
09/20
06:59
09/20/17
06:59
Technical Analysis
Technical View: Aluminum Corp. of China at new 52-week high in pre-market »

The stock was last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$94.87

0.49 (0.52%)

06:58
09/20/17
09/20
06:58
09/20/17
06:58
Periodicals
Equifax may be able to spend $1 per customer over data breach, Bloomberg says »

Equifax may be able to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

NBY

NovaBay

$4.45

0.1 (2.30%)

06:54
09/20/17
09/20
06:54
09/20/17
06:54
Hot Stocks
NovaBay receives noncompliance notification from NYSE »

NovaBay Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$156.60

0.83 (0.53%)

06:54
09/20/17
09/20
06:54
09/20/17
06:54
Recommendations
Adobe analyst commentary  »

Jefferies ups Adobe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PZRX

PhaseRx

$0.78

0.055 (7.64%)

06:53
09/20/17
09/20
06:53
09/20/17
06:53
Hot Stocks
PhaseRx argininosuccinate lyase deficiency treatment granted FDA orphan status »

PhaseRx's treatment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWW

iShares MSCI Mexico

$55.65

-0.26 (-0.47%)

06:52
09/20/17
09/20
06:52
09/20/17
06:52
Technical Analysis
Technical View: iShares MSCI Mexico falls, levels to watch »

The iShares MSCI Mexico…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.